

Streamline your patients' access to XOSPATA[®]

Visit <https://astellas.aspnprograms.com> to:

Indication

XOSPATA is indicated for the treatment of adult patients who have relapsed or refractory acute myeloid leukemia (AML) with a FMS-like tyrosine kinase 3 (FLT3) mutation as detected by an FDA-approved test.

WARNING: DIFFERENTIATION SYNDROME

Patients treated with XOSPATA have experienced symptoms of differentiation syndrome, which can be fatal or life-threatening if not treated. Symptoms may include fever, dyspnea, hypoxia, pulmonary infiltrates, pleural or pericardial effusions, rapid weight gain or peripheral edema, hypotension, or renal dysfunction. If differentiation syndrome is suspected, initiate corticosteroid therapy and hemodynamic monitoring until symptom resolution.



Initiate a Benefits
Verification and obtain
Prior Authorization
forms for specific plans



Have covered
prescriptions routed
to an in-network
pharmacy



Track XOSPATA[®]
prescriptions and
get current status
updates

**Create your account and log in to get started.
Have questions? Call us at (844) 632-9272.**

3 steps to prescribe XOSPATA[®] in your provider portal

XOSPATA Support Solutions offers assistance which includes benefit investigations, prior authorization assistance and information about other financial assistance. Once completed, your referral will be submitted to ASPN to evaluate your patient's coverage.

- Track active referral status from script to delivery
- View patient enrollment status and upload supporting documents
- Manage multiple prescribers in a single account

Step 1

Enter patient-specific information and select a Product.

Patient Information *Required field

*First Name: Lisa
*Last Name: Bell

*Address: 789 Loop Lane

*Zip: 07003 *City: Bloomfield *State: NJ

*Date of Birth: 07/05/1954 *Gender: Male Female

*Phone: (111) 111-1111 *Secondary Number: (111) 111-1111

Email Address: bell@gmail.com

Additional Contact: Phone:

*Prescriber: [Dropdown]

*Prescriber Contact: [Dropdown]

[Add New Prescriber](#)

Select Product

XOSPATA[®] (gilteritinib)

40mg capsule

*Diagnosis Code: [Dropdown] *Units: [Dropdown] *Quantity: [Dropdown]

Directions:

STEP 1

Enter patient name and contact information. Indicate XOSPATA[®] dosage, number of tablets, and diagnosis.

Step 2

Enter patient insurance information and add other documentation.

Insurance Information

Primary Insurance (Required)

*Plan Type: Commercial

*Plan Name: Aetna

*Subscriber's Name: Lisa Bell

*Policy #: 111111111 *Group #: 11111

Secondary Insurance (Optional)

*Plan Type: [Dropdown]

Prescription Plan (Required)

*Plan Type: [Dropdown]

Upload Scanned Insurance Card(s)

Assess for the Virus, PDF, JPG, PNG, GIF

[Upload](#) 0 File(s) selected

STEP 2

Enter prescription insurance information and upload relevant documents.

Enrollment Review

Review all selections and proceed by creating a patient workbench.

Patient Information		Product Selection
USA BELL	SEX: FEMALE	XOSPATA [®] 40mg capsule
789 Loop Lane	DATE OF BIRTH: 07/05/1954	Quantity: 90
Bloomfield, NJ 07003	SSN: [Redacted]	Refills: 1
PRIMARY PHONE: (111) 111-1111	CELL PHONE: (111) 111-1111	Diagnosis: 213
EMAIL: bell@gmail.com		
EMERGENCY CONTACT:		

Delivery Option: [Dropdown]

Insurance Information		
PRIMARY INSURANCE	SECONDARY INSURANCE	PRESCRIPTION INSURANCE
Subscriber: Lisa Bell	Subscriber: Aetna	Subscriber: Lisa Bell
Relation to Patient: [Dropdown]	Relation to Patient: [Dropdown]	Relation to Patient: [Dropdown]
GROUP#: 111111111	PHONE: [Redacted]	(111) 111-1111
PERSON CODE: [Redacted]		PERSON CODE: [Redacted]
PHONE: [Redacted]		DOB: 111111111
		GROUP#: 111111111
		PCN: 111111111
		RBRN#: 111111111

Insurance Card: [Upload](#)

Supporting Documentation: [Upload](#)

STEP 3

Review all selections and proceed by creating a product referral.

Indication

XOSPATA is indicated for the treatment of adult patients who have relapsed or refractory acute myeloid leukemia (AML) with a FMS-like tyrosine kinase 3 (FLT3) mutation as detected by an FDA-approved test.

Important Safety Information

Contraindications

XOSPATA is contraindicated in patients with hypersensitivity to gilteritinib or any of the excipients. Anaphylactic reactions have been observed in clinical trials.

WARNING: DIFFERENTIATION SYNDROME

Patients treated with XOSPATA have experienced symptoms of differentiation syndrome, which can be fatal or life-threatening if not treated. Symptoms may include fever, dyspnea, hypoxia, pulmonary infiltrates, pleural or pericardial effusions, rapid weight gain or peripheral edema, hypotension, or renal dysfunction. If differentiation syndrome is suspected, initiate corticosteroid therapy and hemodynamic monitoring until symptom resolution.

Warnings and Precautions

Differentiation Syndrome (See BOXED WARNING) 3% of 319 patients treated with XOSPATA in the clinical trials experienced differentiation syndrome. Differentiation syndrome is associated with rapid proliferation and differentiation of myeloid cells and may be life-threatening or fatal if not treated. Symptoms of differentiation syndrome in patients treated with XOSPATA included fever, dyspnea, pleural effusion, pericardial effusion, pulmonary edema, hypotension, rapid weight gain, peripheral edema, rash, and renal dysfunction. Some cases had concomitant acute febrile neutrophilic dermatosis. Differentiation syndrome occurred as early as 2 days and up to 75 days after XOSPATA initiation and has been observed with or without concomitant leukocytosis. If differentiation syndrome is suspected, initiate dexamethasone 10 mg IV every 12 hours (or an equivalent dose of an alternative oral or IV corticosteroid) and hemodynamic monitoring until improvement. Taper corticosteroids after resolution of symptoms and administer corticosteroids for a minimum of 3 days. Symptoms of differentiation syndrome may recur with premature discontinuation of corticosteroid treatment. If severe signs and/or symptoms persist for more than 48 hours after initiation of corticosteroids, interrupt XOSPATA until signs and symptoms are no longer severe.

Posterior Reversible Encephalopathy Syndrome (PRES) 1% of 319 patients treated with XOSPATA in the clinical trials experienced posterior reversible encephalopathy syndrome (PRES) with symptoms including seizure and altered mental status. Symptoms have resolved after discontinuation of XOSPATA. A diagnosis of PRES requires confirmation by brain imaging, preferably magnetic resonance imaging (MRI). Discontinue XOSPATA in patients who develop PRES.

Prolonged QT Interval XOSPATA has been associated with prolonged cardiac ventricular repolarization (QT interval). 1% of the 317 patients with a post-baseline QTc measurement on treatment with XOSPATA in the clinical trial were found to have a QTc interval greater than 500 msec and 7% of patients had an increase from baseline QTc greater than 60 msec. Perform electrocardiogram (ECG) prior to initiation of treatment with XOSPATA, on days 8 and 15 of cycle 1, and prior to the start of the next two subsequent cycles. Interrupt and reduce XOSPATA dosage in patients who have a QTcF >500 msec. Hypokalemia or hypomagnesemia may increase the QT prolongation risk. Correct hypokalemia or hypomagnesemia prior to and during XOSPATA administration.

Pancreatitis 4% of 319 patients treated with XOSPATA in the clinical trials experienced pancreatitis. Evaluate patients who develop signs and symptoms of pancreatitis. Interrupt and reduce the dose of XOSPATA in patients who develop pancreatitis.

Embryo-Fetal Toxicity XOSPATA can cause embryo-fetal harm when administered to a pregnant woman. Advise females of reproductive potential to use effective contraception during treatment with XOSPATA and for at least 6 months after the last dose of XOSPATA. Advise males with female partners of reproductive potential to use effective contraception during treatment with XOSPATA and for at least 4 months after the last dose of XOSPATA. Pregnant women, patients becoming pregnant while receiving XOSPATA or male patients with pregnant female partners should be apprised of the potential risk to the fetus.

Adverse Reactions

Fatal adverse reactions occurred in 2% of patients receiving XOSPATA. These were cardiac arrest (1%) and one case each of differentiation syndrome and pancreatitis. The most frequent ($\geq 5\%$) nonhematological serious adverse reactions reported in patients were fever (13%), dyspnea (9%), renal impairment (8%), transaminase increased (6%) and noninfectious diarrhea (5%).

7% discontinued XOSPATA treatment permanently due to an adverse reaction. The most common ($>1\%$) adverse reactions leading to discontinuation were aspartate aminotransferase increased (2%) and alanine aminotransferase increased (2%).

The most frequent ($\geq 5\%$) grade ≥ 3 nonhematological adverse reactions reported in patients were transaminase increased (21%), dyspnea (12%), hypotension (7%), mucositis (7%), myalgia/arthritis (7%), and fatigue/malaise (6%).

Other clinically significant adverse reactions occurring in $\leq 10\%$ of patients included: electrocardiogram QT prolonged (9%), hypersensitivity (8%), pancreatitis (5%), cardiac failure (4%), pericardial effusion (4%), acute febrile neutrophilic dermatosis (3%), differentiation syndrome (3%), pericarditis/myocarditis (2%), large intestine perforation (1%), and posterior reversible encephalopathy syndrome (1%).

Lab Abnormalities Shifts to grades 3-4 nonhematologic laboratory abnormalities in XOSPATA treated patients included phosphate decreased (14%), alanine aminotransferase increased (13%), sodium decreased (12%), aspartate aminotransferase increased (10%), calcium decreased (6%), creatine kinase increased (6%), triglycerides increased (6%), creatinine increased (3%), and alkaline phosphatase increased (2%).

Drug Interactions

Combined P-gp and Strong CYP3A Inducers Concomitant use of XOSPATA with a combined P-gp and strong CYP3A inducer decreases XOSPATA exposure which may decrease XOSPATA efficacy. Avoid concomitant use of XOSPATA with combined P-gp and strong CYP3A inducers.

Strong CYP3A inhibitors Concomitant use of XOSPATA with a strong CYP3A inhibitor increases XOSPATA exposure. Consider alternative therapies that are not strong CYP3A inhibitors. If the concomitant use of these inhibitors is considered essential for the care of the patient, monitor patient more frequently for XOSPATA adverse reactions. Interrupt and reduce XOSPATA dosage in patients with serious or life-threatening toxicity.

Drugs that Target 5HT2B Receptor or Sigma Nonspecific Receptor Concomitant use of XOSPATA may reduce the effects of drugs that target the 5HT2B receptor or the sigma nonspecific receptor (e.g., escitalopram, fluoxetine, sertraline). Avoid concomitant use of these drugs with XOSPATA unless their use is considered essential for the care of the patient.

Specific Populations

Lactation: Advise women not to breastfeed during treatment with XOSPATA and for 2 months after the last dose.

PLEASE VISIT XOSPATA.COM/PI FOR FULL PRESCRIBING INFORMATION, INCLUDING BOXED WARNING.

